Information about the Company
Founded in 1966, Lotus Pharmaceutical Co., Ltd. (Lotus) is currently the largest pharmaceutical company in Taiwan with high-value generic products covering CNS, CVS, women’s health, and antiobesity drugs in tablets and hard/ soft gel capsules with a special focus on oral oncology for global markets. By leveraging a best-inclass R&D and manufacturing platform in Asia, Lotus aims to benefit patients, its employees, and stakeholders. Furthermore, Lotus can reach nearly every global market with its high-value pipeline through its direct markets, currently encompassing Taiwan, Korea, Thailand, Vietnam, Singapore, Hong Kong, Malaysia, Philippines, and China, or via alliances with top-tier pharma companies based on its industryleading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus will continue to deliver on its strategy and remain steadfast in its mission to improve people’s lives by expanding access to affordable medicines globally through the promise of generic pharmaceuticals.
Company Culture & Company Activities
Lotus constantly strives to make a difference, not only in work but in communities around the world as well. Better Planet is Lotus’s global corporate social responsibility program that builds on the mission of making people’s lives better by addressing important social issues and making high-quality medicines more accessible around the globe. Lotus dedicates itself to high-value and affordable drugs for global patients, not only for sales and profits but also for CSR practice.
By collaborating with various corporate resources, Lotus proactively follows the United Nation’s “Sustainable Development Goals (SDGs) - Health and Wellbeing of SDG03, Employment and Economic Growth of SDG08, and Reduces Inequality of SDG10” guidance, to gradually reduce patients’ medical expenses burden, treatment delays caused by personal financial worries, and other social costs.
Founded in 1966, Lotus Pharmaceutical Co., Ltd. (Lotus) is currently the largest pharmaceutical company in Taiwan with high-value generic products covering CNS, CVS, women’s health, and antiobesity drugs in tablets and hard/ soft gel capsules with a special focus on oral oncology for global markets. By leveraging a best-inclass R&D and manufacturing platform in Asia, Lotus aims to benefit patients, its employees, and stakeholders. Furthermore, Lotus can reach nearly every global market with its high-value pipeline through its direct markets, currently encompassing Taiwan, Korea, Thailand, Vietnam, Singapore, Hong Kong, Malaysia, Philippines, and China, or via alliances with top-tier pharma companies based on its industryleading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus will continue to deliver on its strategy and remain steadfast in its mission to improve people’s lives by expanding access to affordable medicines globally through the promise of generic pharmaceuticals.
Company Culture & Company Activities
Lotus constantly strives to make a difference, not only in work but in communities around the world as well. Better Planet is Lotus’s global corporate social responsibility program that builds on the mission of making people’s lives better by addressing important social issues and making high-quality medicines more accessible around the globe. Lotus dedicates itself to high-value and affordable drugs for global patients, not only for sales and profits but also for CSR practice.
By collaborating with various corporate resources, Lotus proactively follows the United Nation’s “Sustainable Development Goals (SDGs) - Health and Wellbeing of SDG03, Employment and Economic Growth of SDG08, and Reduces Inequality of SDG10” guidance, to gradually reduce patients’ medical expenses burden, treatment delays caused by personal financial worries, and other social costs.
Lotus’s vision is to become a global leader in developing and manufacturing oral oncology products and a preferred partner in the world.
Achievements & Impact
With an aim to become a preferred global oncology and specialty generics partner, Lotus has grown from a small single-market company to now an Asian-based regional player with global reach. Lotus currently has more than 250 products in the on-market portfolio covering 40 countries around the world and deploys 50 more projects in the pipeline to launch for additional 40 markets by 2025.
In just 7 years, its sales have increased by 129% and turned into profits with sustainable growth. In 2022, Lotus received the HR Asia “Best Companies to Work for in Asia.” Being the Best Employer has always been a critical pillar in Lotus’s strategic STAR MAP, including five main pillars — Best Portfolio, Best Quality, Best Service, Low Cost, and Best People, to support its growth strategy and serve as the framework for the focus areas and actions that are needed to become a global leader. For Lotus, PEOPLE are one of the important drivers of success. The number of Lotus’s employees has been increasing significantly since 2014 and has now reached over 1,200 employees across the region with 23 different nationalities, cultural backgrounds, and races.
Lotus takes diversity, gender equality, and respect seriously and keeps building up the desired world-class company culture and working atmosphere to accommodate global employees and provide keep-growing opportunities moving forward.
Future Direction
In order to become a global leader and preferred partner, Lotus will continue to keep the quality of the product selection process and robust pipeline, ensure the excellence of manufacturing, and proactively support brand acquisitions, in-licensing, out-licensing, and distribution deals with partners globally.
Additionally, the company will demonstrate the ability to navigate IP, regulatory, and market access to secure successful product launch, show a strong B2C presence in APAC and B2B commercial networks in the US, Europe, Japan, Latin America, and the Middle East, and build a competent and experienced management team with a proven track record of driving commercial success globally.
With an aim to become a preferred global oncology and specialty generics partner, Lotus has grown from a small single-market company to now an Asian-based regional player with global reach. Lotus currently has more than 250 products in the on-market portfolio covering 40 countries around the world and deploys 50 more projects in the pipeline to launch for additional 40 markets by 2025.
In just 7 years, its sales have increased by 129% and turned into profits with sustainable growth. In 2022, Lotus received the HR Asia “Best Companies to Work for in Asia.” Being the Best Employer has always been a critical pillar in Lotus’s strategic STAR MAP, including five main pillars — Best Portfolio, Best Quality, Best Service, Low Cost, and Best People, to support its growth strategy and serve as the framework for the focus areas and actions that are needed to become a global leader. For Lotus, PEOPLE are one of the important drivers of success. The number of Lotus’s employees has been increasing significantly since 2014 and has now reached over 1,200 employees across the region with 23 different nationalities, cultural backgrounds, and races.
Lotus takes diversity, gender equality, and respect seriously and keeps building up the desired world-class company culture and working atmosphere to accommodate global employees and provide keep-growing opportunities moving forward.
Future Direction
In order to become a global leader and preferred partner, Lotus will continue to keep the quality of the product selection process and robust pipeline, ensure the excellence of manufacturing, and proactively support brand acquisitions, in-licensing, out-licensing, and distribution deals with partners globally.
Additionally, the company will demonstrate the ability to navigate IP, regulatory, and market access to secure successful product launch, show a strong B2C presence in APAC and B2B commercial networks in the US, Europe, Japan, Latin America, and the Middle East, and build a competent and experienced management team with a proven track record of driving commercial success globally.
CORPORATE EXCELLENCE CATEGORY
Lotus Pharmaceutical Co., Ltd.
Information about the Company
Founded in 1966, Lotus Pharmaceutical Co., Ltd. (Lotus) is currently the largest pharmaceutical company in Taiwan with high-value generic products covering CNS, CVS, women’s health, and antiobesity drugs in tablets and hard/ soft gel capsules with a special focus on oral oncology for global markets. By leveraging a best-inclass R&D and manufacturing platform in Asia, Lotus aims to benefit patients, its employees, and stakeholders. Furthermore, Lotus can reach nearly every global market with its high-value pipeline through its direct markets, currently encompassing Taiwan, Korea, Thailand, Vietnam, Singapore, Hong Kong, Malaysia, Philippines, and China, or via alliances with top-tier pharma companies based on its industryleading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus will continue to deliver on its strategy and remain steadfast in its mission to improve people’s lives by expanding access to affordable medicines globally through the promise of generic pharmaceuticals.
Company Culture & Company Activities
Lotus constantly strives to make a difference, not only in work but in communities around the world as well. Better Planet is Lotus’s global corporate social responsibility program that builds on the mission of making people’s lives better by addressing important social issues and making high-quality medicines more accessible around the globe. Lotus dedicates itself to high-value and affordable drugs for global patients, not only for sales and profits but also for CSR practice.
By collaborating with various corporate resources, Lotus proactively follows the United Nation’s “Sustainable Development Goals (SDGs) - Health and Wellbeing of SDG03, Employment and Economic Growth of SDG08, and Reduces Inequality of SDG10” guidance, to gradually reduce patients’ medical expenses burden, treatment delays caused by personal financial worries, and other social costs.
Founded in 1966, Lotus Pharmaceutical Co., Ltd. (Lotus) is currently the largest pharmaceutical company in Taiwan with high-value generic products covering CNS, CVS, women’s health, and antiobesity drugs in tablets and hard/ soft gel capsules with a special focus on oral oncology for global markets. By leveraging a best-inclass R&D and manufacturing platform in Asia, Lotus aims to benefit patients, its employees, and stakeholders. Furthermore, Lotus can reach nearly every global market with its high-value pipeline through its direct markets, currently encompassing Taiwan, Korea, Thailand, Vietnam, Singapore, Hong Kong, Malaysia, Philippines, and China, or via alliances with top-tier pharma companies based on its industryleading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus will continue to deliver on its strategy and remain steadfast in its mission to improve people’s lives by expanding access to affordable medicines globally through the promise of generic pharmaceuticals.
Company Culture & Company Activities
Lotus constantly strives to make a difference, not only in work but in communities around the world as well. Better Planet is Lotus’s global corporate social responsibility program that builds on the mission of making people’s lives better by addressing important social issues and making high-quality medicines more accessible around the globe. Lotus dedicates itself to high-value and affordable drugs for global patients, not only for sales and profits but also for CSR practice.
By collaborating with various corporate resources, Lotus proactively follows the United Nation’s “Sustainable Development Goals (SDGs) - Health and Wellbeing of SDG03, Employment and Economic Growth of SDG08, and Reduces Inequality of SDG10” guidance, to gradually reduce patients’ medical expenses burden, treatment delays caused by personal financial worries, and other social costs.
Lotus’s vision is to become a global leader in developing and manufacturing oral oncology products and a preferred partner in the world.
Achievements & Impact
With an aim to become a preferred global oncology and specialty generics partner, Lotus has grown from a small single-market company to now an Asian-based regional player with global reach. Lotus currently has more than 250 products in the on-market portfolio covering 40 countries around the world and deploys 50 more projects in the pipeline to launch for additional 40 markets by 2025.
In just 7 years, its sales have increased by 129% and turned into profits with sustainable growth. In 2022, Lotus received the HR Asia “Best Companies to Work for in Asia.” Being the Best Employer has always been a critical pillar in Lotus’s strategic STAR MAP, including five main pillars — Best Portfolio, Best Quality, Best Service, Low Cost, and Best People, to support its growth strategy and serve as the framework for the focus areas and actions that are needed to become a global leader. For Lotus, PEOPLE are one of the important drivers of success. The number of Lotus’s employees has been increasing significantly since 2014 and has now reached over 1,200 employees across the region with 23 different nationalities, cultural backgrounds, and races.
Lotus takes diversity, gender equality, and respect seriously and keeps building up the desired world-class company culture and working atmosphere to accommodate global employees and provide keep-growing opportunities moving forward.
Future Direction
In order to become a global leader and preferred partner, Lotus will continue to keep the quality of the product selection process and robust pipeline, ensure the excellence of manufacturing, and proactively support brand acquisitions, in-licensing, out-licensing, and distribution deals with partners globally.
Additionally, the company will demonstrate the ability to navigate IP, regulatory, and market access to secure successful product launch, show a strong B2C presence in APAC and B2B commercial networks in the US, Europe, Japan, Latin America, and the Middle East, and build a competent and experienced management team with a proven track record of driving commercial success globally.
With an aim to become a preferred global oncology and specialty generics partner, Lotus has grown from a small single-market company to now an Asian-based regional player with global reach. Lotus currently has more than 250 products in the on-market portfolio covering 40 countries around the world and deploys 50 more projects in the pipeline to launch for additional 40 markets by 2025.
In just 7 years, its sales have increased by 129% and turned into profits with sustainable growth. In 2022, Lotus received the HR Asia “Best Companies to Work for in Asia.” Being the Best Employer has always been a critical pillar in Lotus’s strategic STAR MAP, including five main pillars — Best Portfolio, Best Quality, Best Service, Low Cost, and Best People, to support its growth strategy and serve as the framework for the focus areas and actions that are needed to become a global leader. For Lotus, PEOPLE are one of the important drivers of success. The number of Lotus’s employees has been increasing significantly since 2014 and has now reached over 1,200 employees across the region with 23 different nationalities, cultural backgrounds, and races.
Lotus takes diversity, gender equality, and respect seriously and keeps building up the desired world-class company culture and working atmosphere to accommodate global employees and provide keep-growing opportunities moving forward.
Future Direction
In order to become a global leader and preferred partner, Lotus will continue to keep the quality of the product selection process and robust pipeline, ensure the excellence of manufacturing, and proactively support brand acquisitions, in-licensing, out-licensing, and distribution deals with partners globally.
Additionally, the company will demonstrate the ability to navigate IP, regulatory, and market access to secure successful product launch, show a strong B2C presence in APAC and B2B commercial networks in the US, Europe, Japan, Latin America, and the Middle East, and build a competent and experienced management team with a proven track record of driving commercial success globally.